A Pilot, Phase II, Single Center, Non-Comparative, Open-Label Study of Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer.
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2010
At a glance
- Drugs Exemestane (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Oct 2006 New trial record.